81 FR 41585 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 123 (June 27, 2016)

Page Range		41585-41586
FR Document		2016-15059

The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.

Federal Register, Volume 81 Issue 123 (Monday, June 27, 2016)

[Federal Register Volume 81, Number 123 (Monday, June 27, 2016)]
[Notices]
[Pages 41585-41586]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-15059]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD 20850-9702, Tel. 240-276-5515 or email 
[email protected]. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Biomarker signature development: microRNAs as 
biodosimetry markers.
    Description of Technology:
    Alterations in microRNAs (miRNAs), a type of small non-coding RNAs, 
have been reported in cells/tumors subjected to radiation exposure, 
implying that miRNAs play an important role in cellular stress response 
to radiation.
    Researchers at the National Cancer Institute evaluated small non-
coding RNAs, long non-coding RNAs (lncRNA), and mRNA as potential non-
invasive biomarkers for radiation biodosimetry. While the use of miRNAs 
as radiation biomarkers has been reported, the integrated use of 
miRNAs, mRNAs and lncRNAs to accurately determine radiation doses is 
novel and has not been published. The researchers characterized a 
unique method of examining miRNA levels along with levels of its target 
mRNA and lncRNA to determine radiation exposure using whole blood 
samples from mice exposed to 2, 4, 8, 12 and 15 Gy irradiation. In 
doing so, they discovered distinct miRNA, mRNA and lncRNA biomarker 
signatures that inform degree of radiation exposure.

[[Page 41586]]

    Integrated analysis of miRNA, mRNAs, and lncRNAs to assess 
radiation exposure after mass-casualty incidents could provide a 
valuable tool in identifying biomarkers, and in the development and 
appropriate implementation of effective medical countermeasures. This 
application could potentially also be used to immediately detect, and 
therefore circumvent or mitigate non-specific injury from cancer 
radiotherapy treatments.
    Potential Commercial Applications:
     Diagnostic for radiation exposure, including for 
therapeutic procedures.
    Value Proposition:
     Blood-based biomarker assay for circulating miRNAs.
     Could be developed as part of point-of-care and high-
throughput screening platforms.
     Immediate medical care based on amount of radiation 
exposure is critical for giving appropriate care to affected 
individuals.
    Development Stage:
    In-vivo testing.
    Inventor(s):
    Molykutty Aryankalayil (NCI), Norman Coleman (NCI), Adeola Makinde 
(NCI).
    Intellectual Property:
    HHS Reference No. E-066-2015/0-US-01 US Provisional Application 62/
244,044 (HHS Reference No. E-066-2016/0-US-01) filed October 20, 2015 
entitled ``Biomarker signature development: microRNAs as biodosimetry 
markers''
    Collaboration Opportunity: Researchers at the NCI seek parties 
interested in licensing or co-development for microRNA biomarker 
signatures as biodosimetry markers.
    Contact Information:
    Requests for copies of the patent application or inquiries about 
licensing, research collaborations, and co-development opportunities 
should be sent to John D. Hewes, Ph.D., email: [email protected] or 
phone: 240-276-5515.

    Dated: June 20, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-15059 Filed 6-24-16; 8:45 am]
BILLING CODE 4140-01-P

41586 Federal Register / Vol. 81, No. 123 / Monday, June 27, 2016 / Notices

Integrated analysis of miRNA, DEPARTMENT OF HEALTH AND Contact Person: Robert Finkelstein, Ph.D.,
mRNAs, and lncRNAs to assess HUMAN SERVICES Director of Extramural Research, National
Institute of Neurological Disorders and
radiation exposure after mass-casualty
National Institutes of Health Stroke, NIH, 6001 Executive Blvd., Suite
incidents could provide a valuable tool 3309, MSC 9531, Bethesda, MD 20892, (301)
in identifying biomarkers, and in the 496–9248.
National Institute of Neurological
development and appropriate Any interested person may file written
Disorders and Stroke; Notice of
implementation of effective medical comments with the committee by forwarding
Meeting
countermeasures. This application the statement to the Contact Person listed on
could potentially also be used to Pursuant to section 10(d) of the this notice. The statement should include the
immediately detect, and therefore Federal Advisory Committee Act, as name, address, telephone number and when
applicable, the business or professional
circumvent or mitigate non-specific amended (5 U.S.C. App.), notice is
affiliation of the interested person.
injury from cancer radiotherapy hereby given of a meeting of the In the interest of security, NIH has
treatments. National Advisory Neurological instituted stringent procedures for entrance
Disorders and Stroke Council. onto the NIH campus. All visitor vehicles,
Potential Commercial Applications:
The meeting will be open to the including taxicabs, hotel, and airport shuttles
• Diagnostic for radiation exposure, public as indicated below, with will be inspected before being allowed on
including for therapeutic procedures. attendance limited to space available. campus. Visitors will be asked to show one
Individuals who plan to attend and form of identification (for example, a
Value Proposition: government-issued photo ID, driver’s license,
need special assistance, such as sign
• Blood-based biomarker assay for or passport) and to state the purpose of their
language interpretation or other visit.
circulating miRNAs.
reasonable accommodations, should Information is also available on the
• Could be developed as part of notify the Contact Person listed below Institute’s/Center’s home page: http://
point-of-care and high-throughput in advance of the meeting. www.ninds.nih.gov, where an agenda and
screening platforms. The meeting will be closed to the any additional information for the meeting
• Immediate medical care based on public in accordance with the will be posted when available.
amount of radiation exposure is critical provisions set forth in sections (Catalogue of Federal Domestic Assistance
for giving appropriate care to affected 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Program Nos. 93.853, Clinical Research
as amended. The grant applications and Related to Neurological Disorders; 93.854,
individuals. Biological Basis Research in the
the discussions could disclose
Development Stage: confidential trade secrets or commercial Neurosciences, National Institutes of Health,
HHS).
In-vivo testing. property such as patentable materials,
and personal information concerning Dated: June 21, 2016.
Inventor(s):
individuals associated with the grant Sylvia L. Neal,
Molykutty Aryankalayil (NCI), applications, the disclosure of which Program Analyst, Office of Federal Advisory
Norman Coleman (NCI), Adeola would constitute a clearly unwarranted Committee Policy.
Makinde (NCI). invasion of personal privacy. [FR Doc. 2016–15068 Filed 6–24–16; 8:45 am]
Intellectual Property: Name of Committee: National Advisory BILLING CODE 4140–01–P

HHS Reference No. E–066–2015/0– Neurological Disorders and Stroke Council.
US–01 US Provisional Application 62/ Date: September 15–16, 2016.
Open: September 15, 2016, 8:00 a.m. to DEPARTMENT OF HEALTH AND
244,044 (HHS Reference No. E–066– 2:30 p.m. HUMAN SERVICES
2016/0–US–01) filed October 20, 2015 Agenda: Report by the Director, NINDS;
entitled ‘‘Biomarker signature Report by the Associate Director for National Institutes of Health
development: microRNAs as Extramural Research; Administrative and
biodosimetry markers’’ Program Developments; and an Overview of Center for Scientific Review; Notice of
the NINDS Intramural Program. Closed Meetings
Collaboration Opportunity: Place: National Institutes of Health,
Researchers at the NCI seek parties Building 31, 31 Center Drive, 6th Floor, Pursuant to section 10(d) of the
interested in licensing or co- Conference Room 10, Bethesda, MD 20892. Federal Advisory Committee Act, as
development for microRNA biomarker Closed: September 15, 2016, 2:30 p.m. to amended (5 U.S.C. App.), notice is
signatures as biodosimetry markers. 4:45 p.m. hereby given of the following meetings.
Agenda: To review and evaluate grant The meetings will be closed to the
Contact Information: applications. public in accordance with the
Requests for copies of the patent Place: National Institutes of Health, provisions set forth in sections
application or inquiries about licensing, Building 31, 31 Center Drive, 6th Floor,
Conference Room 10, Bethesda, MD 20892.
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
research collaborations, and co- as amended. The grant applications and
Closed: September 15, 2016, 4:45 p.m. to
development opportunities should be 5:15 p.m. the discussions could disclose
sent to John D. Hewes, Ph.D., email: Agenda: To review and evaluate the confidential trade secrets or commercial
john.hewes@nih.gov or phone: 240–276– Division of Intramural Research Board of property such as patentable material,
5515. Scientific Counselors’ Reports. and personal information concerning
Place: National Institutes of Health, individuals associated with the grant
Dated: June 20, 2016. Building 31, 31 Center Drive, 6th Floor,
mstockstill on DSK3G9T082PROD with NOTICES

applications, the disclosure of which
John D. Hewes, Conference Room 10, Bethesda, MD 20892. would constitute a clearly unwarranted
Technology Transfer Specialist, Technology Closed: September 16, 2016, 8:00 a.m. to
11:00 a.m.
invasion of personal privacy.
Transfer Center, National Cancer Institute.
Agenda: To review and evaluate grant Name of Committee: AIDS and Related
[FR Doc. 2016–15059 Filed 6–24–16; 8:45 am]
applications. Research Integrated Review Group; AIDS
BILLING CODE 4140–01–P Place: National Institutes of Health, Molecular and Cellular Biology Study
Building 31, 31 Center Drive, 6th Floor, Section.
Conference Room 10, Bethesda, MD 20892. Date: July 18, 2016.

VerDate Sep<11>2014 20:12 Jun 24, 2016 Jkt 238001 PO 00000 Frm 00079 Fmt 4703 Sfmt 4703 E:\FR\FM\27JNN1.SGM 27JNN1

Document Created: 2016-06-25 02:07:09
Document Modified: 2016-06-25 02:07:09

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Information on licensing and co- development research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or email [email protected] A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
FR Citation		81 FR 41585

81 FR 41585 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 123 (June 27, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health